UN

Break free.

about us

Vision

Deliver killer tools to unleash science.

Path

Uncover scientific problems.
Solve them. Period.

People

The right group of people can accomplish anything.

"Freedom lies in being bold."

- Robert Frost

Products

Events

CONFERENCES & WORKSHOPS

RNA Therapeutics & Delivery US: Online

Jun 29-30, Virtual Event. Register.

Bioprocessing Summit

Aug 16-19, Boston, US, Booth 607 Register.

Inhalation Drug Delivery Systems

Dec 7-8, San Diego. Register.

UPCOMING WEBINARS

Virtual Seminar: Beef up your protein formulation toolbox with Uncle

Jun 23, 2021, 8 am PT, 11 am ET, 5 pm CET Register.

GEN Webinar: Take the hassle out of nanoparticle prep and characterization with Big Tuna and Stunner

Jul 28, 2021, Jul 28, 2021, 8 am PT, 11 am ET, 5 pm CET Register.


PAST WEBINARS

LabRoots Webinar: Fast-track your biologics and NGS workflows with automated UV/Vis quant on Lunatic

Jun 11, 2021, 8 am PT, 11 am ET, 5 pm CET Watch recording.

Lab Automation Seminar: Paul Clark, Dow

May 25, 2021, 8 am PT, 11 am ET, 5 pm CET Watch recording.

Lab Automation Seminar: Georg Wuitschik, Roche

May 18, 2021, 8 am PT, 11 am ET, 5 pm CET Watch recording.

Lab Automation Seminar: Princeton University & Bristol-Myers Squibb

May 11, 2021, 8 am PT, 11 am ET, 5 pm CET Watch recording.

Select Science Webinar: Off-load gene therapy and vaccine buffer exchange to Big Tuna

Apr 29, 2021 Watch recording.

Virtual Seminar: Sound the alarm on protein aggregation with Stunner

Apr 22, 2021 Watch recording.

Watch more PAST WEBINARS on demand.

News

Jun 3, 2021

Unchained Labs adds industry vets to get big fast! Read more.

Unchained Labs adds industry vets to get big fast!

June 3, 2021 – Pleasanton, CA – Unchained Labs, the life science tools company that’s all about getting biologics and gene therapy researchers the right tools for the job, today announced the additions of Tom O’Lenic as Chief Commercial Officer and Don Phelps as VP Finance.

Tom has been building successful life science tools companies since the 1990’s. He built and led sales teams at Molecular Devices before becoming General Manager of the entire business after it was acquired. He then led the sequencing unit and commercial operations for IntegenX. From there he became the Chief Commercial Officer of Advanced Cell Diagnostics and again became the General Manager of the business after it was acquired.

Don was Director of Finance for ProteinSimple before it was acquired. He stayed with the business after acquisition and helped scale the finance and accounting team of the division to support over $200M in revenue. He then led the Finance and Operations team at Intabio from initial scale up through the sale of the business.

“We are completely focused on getting big fast, and we need people in our tribe who know how to do that,” said Tim Harkness, Founder and CEO of Unchained. “Tom and Don are those people. I have known them both for over a decade and I am thrilled to have them join the Unchained tribe for the next phase of our journey. I know they will help us scale and navigate the challenges of the hyper growth to come.”

Tom and Don said in unison, “We are totally stoked to join the Unchained tribe!”

About Unchained Labs

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
Taegen.clary@unchainedlabs.com
925.587.9800

Download PDF of the press release.

Apr 26, 2021

The Carlyle Group to acquire rapidly growing life sciences tools company Unchained Labs Read more.

The Carlyle Group to acquire rapidly growing life sciences tools company Unchained Labs

April 26, 2021 – Pleasanton, CA – Global investment firm The Carlyle Group (NASDAQ:CG) today announced that it has agreed to acquire the rapidly growing life sciences tools company Unchained Labs for $435 million, in partnership with its management team, from Novo Holdings A/S, Canaan Partners and TPG Biotech. The transaction is subject to regulatory approvals and is expected to close in Q2 2021.

Founded in 2015 and headquartered in Pleasanton, CA, Unchained Labs is a life science tools company focused on solving problems for biologics and gene therapy researchers. Unchained systems are used by biopharma researchers around the world to analyze and characterize large, complex molecules and to make their research jobs easier. Unchained has 170 employees and expects to generate over $75 million of revenue in 2021.

“This is a great day in the history of Unchained Labs,” said Tim Harkness, Unchained Labs Founder and CEO. “The Unchained team has solved a ton of problems for researchers over the past few years, but we are just beginning to scratch the surface of the biologics and gene therapy opportunity. I am thrilled to welcome Carlyle as our new partner! They have the team, the vision, the conviction, the experience, and the capital to help us accelerate organic and inorganic growth and realize our full potential. I have never been more optimistic about our future and I am truly excited about joining Carlyle for the next part of our journey.”

“Unchained Labs sits at the intersection of one of the most attractive sectors in healthcare, life science tools, and its fastest growing end market, biopharma,” said Steve Wise, Global Head of Healthcare at Carlyle. “With strong industry tailwinds, we believe Unchained Labs has significant growth opportunities and we’re excited to support another founder-backed business to scale through investments in research and development, digitization and geographic expansion.”

“In the midst of the genomic revolution, Unchained Labs is on a mission to bring highly innovative products that are critical to drug development to researchers globally,” said Robert Schmidt, a Managing Director specializing in healthcare investing at Carlyle. “We look forward to partnering with Tim and his impressive management team as they help their pharma and biotech customers work on critical scientific discoveries and accelerate the Company’s aggressive growth plans.”

The investment in Unchained Labs is a continuation of Carlyle’s long-term global commitment to healthcare, in which it has invested more than $16 billion of equity since inception. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare.

J.P. Morgan Securities LLC acted as financial advisor and Cooley LLP acted as legal counsel to Unchained Labs. Citi acted as financial advisor and Kirkland & Ellis LLP acted as legal counsel to Carlyle.

About the Carlyle Group
The Carlyle Group (NASDAQ:CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions. With $246 billion of assets under management as of December 31, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and communities in which we live and invest. The Carlyle Group employs 1,825 people in 29 offices across five continents. Further information is available at www.carlyle.com. Follow The Carlyle Group on Twitter @OneCarlyle. 

About Unchained Labs
Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Carlyle Contact:
Brittany Berliner
Brittany.berliner@carlyle.com
+1(212) 813-4839

Unchained Labs Contact:
Tim Harkness
Founder and CEO
tim.harkness@unchainedlabs.com
+1(925) 587-9800

Download PDF of the press release.

Apr 1, 2021

Unchained Labs makes another big splash with Big Tuna in gene therapy and vaccines! Read more.

Unchained Labs makes another big splash with Big Tuna in gene therapy and vaccines!

April 1, 2021 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched its new gene therapy and vaccine applications on the Big Tuna platform today. Big Tuna is already the ultimate buffer exchange platform for biologics, and now it can take on buffer exchange, concentration and clean-up of adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs).

AAVs are produced at low concentrations and need to be concentrated up for characterization. LNPs are made in the presence of ethanol which needs to be cleared out quickly to keep them stable. Both are tough to handle due to their large size and how fast their buffers flow through filtration membranes. Big Tuna’s new high molecular weight cutoff plates, concentration application and tunable pressure settings make it perfectly dialed in for these molecules.

“The use of AAVs and LNPs for gene therapies and vaccines is literally booming,” said Taegen Clary, VP of Marketing at Unchained Labs. “Researchers developing these complex molecules need better tools to clean them up, concentrate to dosable levels and get them into formulations that solve cold chain issues. With the new features on Big Tuna, researchers can now fully automate these steps in their workflow and ditch the slow and manual ways of the past.”

About Unchained Labs

Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9800

Download PDF of press release.

Jan 11, 2021

Unchained Labs sticks it to viruses, launches new mRNA vaccine application on Stunner! Read more.

Unchained Labs sticks it to viruses, launches new mRNA vaccine application on Stunner!

January 11, 2021 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched its new mRNA vaccine application on Stunner today. Stunner is the only platform that can simultaneously quantify the total amount of mRNA and measure the size distribution of lipid nanoparticles – two critical qualities of these novel vaccines.

Stunner’s super short pathlength for UV/Vis and DLS makes it the perfect tool for measuring both the mRNA concentration and the lipid nanoparticle (LNP) size in these typically cloudy samples. It gets it done straight up, with no dilutions, completely label-free and can crank through 96 samples in an hour using only 2 µL of these very precious samples.

“LNPs need to be just the right size to deliver mRNA for a solid immune response,” said Taegen Clary, VP of Marketing at Unchained Labs. “Researchers working on these challenging molecules are in urgent need of better analytical tools that can keep up with their crazy pace. Stunner is the accurate, hassle-free, high-throughput quantification and sizing platform they’ve been thirsting for.”

About Unchained Labs

Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Oct 6, 2020

Unchained Labs launches the ultimate gene therapy tool; tackle AAV titer, empty/full ratio and more with Stunner! Read more.

Unchained Labs launches the ultimate gene therapy tool; tackle AAV titer, empty/full ratio and more with Stunner!

October 6, 2020 – Pleasanton, CA – Unchained Labs, the life sciences company that’s all about getting researchers the right tool for the job, launched its new gene therapy quantification application on Stunner today. Stunner is the first platform that gives researchers a full read-out on how many AAV capsids they have, how many are packed with DNA and if there is aggregation – in less than a minute using only 2 µL of sample.

Adeno-associated viruses (AAVs) used in gene therapies are hard to manufacture and tough to characterize.  Researchers need to be able to quickly and accurately measure their capsid titer, and how many of them are full of DNA they are supposed to deliver to cells. Other methods that gather this info require labels, dyes, reagents, standard curves or use a lot of sample. Pulling it all together is a big lift and takes way too long with existing technologies.

Stunner makes AAV titer a snap. Researchers just pipette 2 µL of their sample, up to 96 samples per run, and then Stunner takes it from there. UV/Vis measures the total protein and DNA in the sample. Dynamic light scattering identifies AAV capsids based on their size and checks for aggregation. Stunner then combines all this information to provide an accurate titer and empty/full ratio.

“Gene therapy researchers are hungry for better tools and Stunner delivers all the data they need,” said Taegen Clary, VP of Marketing at Unchained Labs. “No other instrument quantifies AAV capsids, both full and empty, and can see aggregates. These complex molecules demand that traditional techniques be reimagined or combined to provide better insights, and with Stunner’s AAV application we’ve done both.”

About Unchained Labs

Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it. We’re located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:

Taegen Clary
VP of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
925.587.9806

Download PDF of press release.

Our Tribe

READ BIO

Tim Harkness

Founder and CEO
Tim Harkness, Founder and CEO

Building great teams and great life sciences companies is just in Tim’s DNA. He brings 25+ years of life science leadership experience to the Unchained Labs table and has 3 successful exits under his belt. He founded Unchained Labs to solve problems for biologics and gene therapy researchers and in 6 years the team built a $60M+ business and transitioned to the next phase of growth by partnering with Carlyle in a $435M deal. At ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch and sold it for $300M. Prior to that he helped build Molecular Devices into a diversified life science tools provider and sold it for over $600M. He has raised nearly $200M of venture capital, helped raise over $1B in the public equity markets and has been a part of 4 successful exits as an independent board member. He is an enthusiastic supporter of other entrepreneurial teams and he is currently an Independent Director at LabVoice. He has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children and you can find him out hacking around on the links or riding his bike whenever he can.

READ BIO

Krista Witte

VP Product Dev
Krista Witte, VP Product Dev

Krista loves building assays and analytical tools to do great science. She has over 15 years of experience in life sciences instrumentation and application development. Prior to joining Unchained Labs, Krista was a founding team member of ForteBio, now Pall ForteBio. In her decade at the company, she held many roles including heading up Applications, Assay Development, System Integration, QC and R&D. She saw the company from angel-funded start-up to a leading provider of label-free instrumentation. Prior to ForteBio, Krista headed up the Applications team at Zyomyx, taking a lead role in developing their protein microarray technology. Krista holds a Ph.D. in Carbohydrate Chemistry from The Scripps Research Institute and a B.S. in Chemistry from Texas A&M (Gig ‘em Aggies!). When not doing science, Krista is obsessed with being around the water and can be found swimming, diving or sailing.

READ BIO

Taegen Clary

VP Marketing
Taegen Clary, VP Marketing

Taegen loves marketing life science tools. He has over 15 years of experience using and marketing enabling life science instrumentation and consumables. As the Director of Pharmaceutical Segment Marketing at Agilent Technologies, he led the marketing organization focused on the company’s largest customer segment, which has experienced consistent, above-market growth rates and 2014 sales revenues of $1B. Over his 7 years at Agilent, Taegen was the Product Manager for Proteomics and Protein Chemistries and also led the Life Science group’s efforts in the area of protein therapeutics. He began his career at Berlex Biosciences, now a part of Bayer Healthcare, running mass spectrometers and developing assays to measure drug passage across the blood brain barrier. Taegen has an M.B.A. in Marketing from St. Mary’s College of California and a B.S. in Biotechnology from the University of California, Davis. Taegen is married with two children, loves mountain biking, camping, fishing, golfing and is huge fan of the San Francisco Giants and 49ers.

READ BIO

Tom O’Lenic

Chief Commercial Officer
Tom O’Lenic, Chief Commercial Officer

Scaling commercial teams to nail growth targets is what gets Tom going. He has over 30 years of experience developing and commercializing disruptive technologies in the life sciences tools, diagnostic and forensic tools markets. Most recently, he was Founder and CEO of Buzzkill Labs and now serves on the Board of Directors. Before that as CCO and General Manager of Advanced Cell Diagnostics, he helped orchestrate explosive revenue growth which led to acquisition by Bio-Techne. Tom has held leadership roles at Molecular Devices, MDS, IntegenX and BioTechne. As a C-level executive, he has helped create over $1B of exit value. Tom is presently Executive Director at GenTegra, LLC and a member of S2 Genomics Commercial Advisory Board. Tom holds a B.S. in Biology from the University of South Florida. When Tom’s not helping his teams crush their goals, he’s likely mentoring future entrepreneurs or can be found outdoors enjoying running, hiking, soccer, tennis or golf.

READ BIO

Steve Cypes

VP Workflow Sales
Steve Cypes, VP Workflow Sales

Steve’s all about building commercial teams that get disruptive technologies into the hands of scientists. He started his career at Merck and has been passionate about getting to the bottom of life science R&D challenges ever since. He leads the global Workflow and QC sales team, collaborating with customers to leverage Unchained Labs’ automated instrumentation and know-how to tackle their biggest development problems. Prior to Unchained Labs, Steve was the VP of Sales for automated workflows at Freeslate, with a focus on biologics and small molecule applications. Before that, Steve held a number of positions at Symyx Technologies, including leadership roles in engineering, product management, contract testing and sales. Steve has a B.S. and M.Eng. in Chemical Engineering from Cornell University, and an MBA from the Johnson School at Cornell. He loves being active outdoors with his wife and 2 kids, playing golf, hiking, running and helps coach youth lacrosse on the side.

READ BIO

Todd Lewis

VP Analytical Sales
Todd Lewis, VP Analytical Sales

Todd can’t wait to dig in and help scientists find ways to hit their research goals. He’s got 20 years under his belt in both direct sales and managing sales teams in the life science instrument space. At Unchained Labs, Todd leads the global Analytical sales team, focusing on bringing tools to researchers in the biologics drug discovery and development arena. Prior to Unchained Labs, Todd was the Director of Sales for North America at MilliporeSigma, where he led the largest-revenue market. Before that, he honed his commercial expertise at companies like BD, PerkinElmer and Guava Technologies. Todd has a B.S. in Biological Sciences from North Carolina State University. In his free time, Todd’s typically on either the soccer field or the volleyball court, and loves traveling with his wife and kids.

READ BIO

Will Lachnit

VP Corporate Dev
Will Lachnit, VP Corporate Dev

Will’s been around the Life Sciences block a time or two, and can’t get enough when it comes to making companies thrive. He has over 25 years of experience in the life sciences industry across multiple functions. Prior to joining Unchained Labs, Will was the Senior Vice President of Global Sales and Solutions Development at Freeslate. Prior to Freeslate, he was the Vice President of Sales and Service for ProteinSimple. While there, his other roles included leadership of the marketing and applications functions and he played a key role in integrating 4 acquisitions. Previously, at Molecular Devices Corporation, Will had leadership roles for the North American Drug Discovery sales organization, an entrepreneurial product development organization in Switzerland, and Corporate Development. Dr. Lachnit started his career in Pharmaceutical R&D in scientific and research management positions at Roche and Syntex, including running a best-in-class HTS organization. He received his M.S. and Ph.D. in Pharmacology and his B.S. in Physiology from the University of California, Davis. Will has a passion for cooking for his family and loves tinkering around in his woodshop.

READ BIO

Dustin Giberson

VP Operations
Dustin Giberson, VP Operations

Dustin lives to build great products, solve tough problems and help make customers successful. He started his career applying automation to advance life science research and then never looked back. He leads the Operations and Global Service & Support organizations including Manufacturing, Tech Support, Field Service, and Contract Testing teams that delivers products to customers and helps them get the most out of their automation and analytics tools. Prior to Unchained Labs, Dustin was head of Operations at Freeslate providing workflow automation tools to biologics, chemicals, and energy researchers. Before that he held leadership positions at Affymetrix and Beckman Coulter developing commercial, high throughput automation systems and assays. Dustin has a B.S. in Biology from the University of Vermont, a Master of Software Engineering from Brandeis University, and an MBA from the University of Massachusetts Lowell. Apart from work, Dustin enjoys traveling, cooking, and being outdoors with his wife and 3 kids and when he’s not doing that you can probably find him at the gym pumping iron while listening to heavy metal.

READ BIO

Don Phelps

VP Finance
Don Phelps, VP Finance

Don loves digging into the details that makes a company tick, managing worldwide finance, accounting, human resources, IT and facilities. Don has over 25 years in senior finance and accounting leadership roles across a broad range of companies and industries. Prior to Unchained Labs, he was Vice President of Finance and Operations at Intabio, a life science tools startup sold to Sciex. Before that, Don was Director of Finance for Bio-Techne’s Analytical Solutions Division, a $200M instrumentation and consumables business. The core of that division was created from the acquisition of ProteinSimple, where Don led the worldwide finance team. Prior to ProteinSimple, Don worked as a consultant for RoseRyan providing interim controller and finance director leadership to a broad variety of startups and emerging growth companies. He has a BA in International Relations from Claremont McKenna College, and an MBA from Santa Clara University. When Don’s not crunching the numbers, he can be found eating up pavement on his bike or out in the boonies on a long backpacking trip.

The right group of people can accomplish anything!

-

jobs

Admin

No positions are currently available.

Product Development

Sr. Software Engineer
Sr. Scientist

 

Build something big with us!

Send Resume

Board

READ BIO

Tim Harkness

Founder and CEO, Unchained Labs
Tim Harkness, Founder and CEO, Unchained Labs

Building great teams and great life sciences companies is just in Tim’s DNA. He brings 25+ years of life science leadership experience to the Unchained Labs table and has 3 successful exits under his belt. He founded Unchained Labs to solve problems for biologics and gene therapy researchers and in 6 years the team built a $60M+ business and transitioned to the next phase of growth by partnering with Carlyle in a $435M deal. At ProteinSimple, Tim and team built a unique protein analysis pure-play from scratch and sold it for $300M. Prior to that he helped build Molecular Devices into a diversified life science tools provider and sold it for over $600M. He has raised nearly $200M of venture capital, helped raise over $1B in the public equity markets and has been a part of 4 successful exits as an independent board member. He is an enthusiastic supporter of other entrepreneurial teams and he is currently an Independent Director at LabVoice. He has an M.B.A. from Stanford and a B.B.A from the University of Wisconsin. Tim is married with 3 children and you can find him out hacking around on the links or riding his bike whenever he can.

READ BIO

Steve Wise

Managing Director and Global Head of Healthcare, The Carlyle Group
Steve Wise, Managing Director and Global Head of Healthcare, The Carlyle Group

Stephen H. Wise is a Managing Director and Global Head of Healthcare at The Carlyle Group. He is based in New York. Since joining Carlyle in 2006, Carlyle’s Healthcare team has invested approximately $15 billion of equity in health care companies around the world. He serves as a member of the board of directors of Albany Molecular Research, Inc., a contract research and drug manufacturing organization, CorroHealth, a business service provider for healthcare companies, MedRisk, a physical therapy-focused workers’ compensation solutions company, Millicent Pharma Limited, a pharmaceutical company, Ortho-Clinical Diagnostics, a global provider of in vitro diagnostic solutions for screening, diagnosing, monitoring and confirming diseases, PPD, Inc., a global contract research organization, Rede D’Or São Luiz S.A., a hospital provider in Brazil, Sedgwick Inc., a global multiline claims management firm, TriNetX, LLC, a global health research network optimizing clinical research, Unchained Labs, LLC, a global life science tools company, and WellDyneRx, LLC, an independent pharmacy benefit manager. Mr. Wise also serves on the Leadership Council of the Harvard School of Public Health. Prior to joining Carlyle, Mr. Wise worked with JLL Partners, a New York-based private equity firm, where he focused on health care-related investments. Previously, he worked with J.W. Childs Associates, a Boston-based private equity firm, and prior to that, in the leveraged finance group of Credit Suisse. Mr. Wise earned a bachelor’s degree in economics and finance from Bucknell University and received his master’s in business administration from Harvard Business School.

READ BIO

Dr. Martin Madaus

Operating Executive, The Carlyle Group
Dr. Martin Madaus, Operating Executive, The Carlyle Group

Dr. Martin D. Madaus is a serial global healthcare CEO, board member, investor and strategy consultant with 30 years of experience in biotech, medical devices, in vitro diagnostics and life sciences tools. He has a track record for delivering outstanding results by transforming large and complex businesses. He currently works for The Carlyle Group as an Operating Executive and serves as Chairman of Ultivue, Inc., Emulate Bio, Lead Director at Quanterix Corporation (QTRX) and Director at Candela Medical.

He was Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (NASDAQ:OCDX) from June 2015 until February of 2019 leading the carve-out from J&J and the business turnaround. Prior to joining Ortho, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to The Carlyle Group. He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation North America from 2000 to 2004. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and served as the President of Roche Diagnostics Canada. Dr. Madaus started his career in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada. Dr. Madaus has extensive public and private company board experience and has served on the board of Mettler-Toledo International Inc. (NYSE: MTD), Covidien PLC (NYSE: COV), Millipore (NYSE:MIL), PPD Inc. (NASDAQ:PPD), Quanterix (NASDAQ: QTRX), Candela Medical, Ultivue Inc. and Emulate Bio.

Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.

READ BIO

Robert Schmidt

Managing Director, The Carlyle Group
Robert Schmidt, Managing Director, The Carlyle Group

Robert R. Schmidt is a Managing Director on the U.S. Buyout team at The Carlyle Group, focused on private equity investments in the healthcare sector. He is based in New York. Since joining Carlyle in 2011, Mr. Schmidt has been involved in a number of the firm’s investments globally, including Beats Electronics, Grand Rounds, MedRisk, One Medical, Ortho Clinical Diagnostics, Sedgwick and Unchained Labs. He is currently a member of the Board of Directors of Grand Rounds, MedRisk, One Medical, Ortho Clinical Diagnostics, and Unchained Labs. Prior to joining Carlyle, Mr. Schmidt worked at Welsh, Carson, Anderson & Stowe, a private equity firm focused on healthcare and technology investments, and Merrill Lynch Global Private Equity, focused on buyouts in North America. Mr. Schmidt received his M.B.A. from Harvard Business School and a B.S. in economics from The Wharton School at the University of Pennsylvania, where he is currently a member of the External Advisory Board at the Leonard Davis Institute of Health Economics.

investors

meme-a-palooza

get in touch

     

    Unchained Labs Boston
    12 Gill Street, S-1350
    Woburn, MA 01801
    (925) 587-9800

    Unchained Labs HQ
    6870 Koll Center Parkway
    Pleasanton, CA 94566
    (925) 587-9800
    (800) 815-6384 (North America)

    Unchained Labs Shanghai
    Room 601, Sandhill Central
    No. 505 Zhangjiang Road
    Pudong New District
    Shanghai, China 201210
    +86-21-33780983
    spacer

    Unchained Labs Tokyo
    PMO Kandaiwamotocho 3rd Floor
    2-9-2 Kandasudacho
    Chiyoda-ku, Tokyo
    1010041 Japan
    +81 3 3536 2811

    Unchained Labs Belgium
    Zwijnaardsesteenweg 312 bus 001
    BE – 9000 Gent, Belgium
    +32 9 397 09 97

     

    Service and Support
    (925) 587-9800
    support@unchainedlabs.com

    Follow us

     

    Need a distributor?

    Find One


    "…they'll never take our FREEDOM!"

    - WILLIAM WALLACE, BRAVEHEART